Emily Passer (@EmilyPasser) header
Emily Passer (@EmilyPasser) profile picture

PR/Comms, @noom. Formerly: @pagayaltd, @nbcnews, @qz, @FT. Sunglasses junkie, candy enthusiast, Rock Chalk. Views are my own. [email protected]

NYC
Joined June 2009
Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)Photo by Emily Passer (@EmilyPasser)
Replying to @EmilyPasser
I'm thrilled to share that I've started as head of communications for @noom, a company sitting at the intersection of health, technology and human behavior and with the power to deeply influence the broader health landscape. 3/4
1
2
226
Emily Passer retweeted
This week on The MM+M Podcast, @Noom CEO Geoff Cook talks “Weight Regain Doesn’t Care,” the impact of the broader Losing for Keeps effort, the role of celebs in GLP-1 marketing and what other examples of GLP-1 advertising have impressed him. mmm-online.com/podcasts/noom…
2
4
170
Emily Passer retweeted
🚨 BREAKING: ELI LILLY GLP-1 PILL - FOUNDAYO - APPROVED FOR USE IN U.K. U.K. BECOMES FIRST COUNTRY IN EUROPE TO GIVE APPROVAL PILL NOT YET AVAILABLE ON NHS $LLY $NVO $HIMS
4
9
142
14,271
Emily Passer retweeted
$HIMS 🚨 BREAKING: FDA PEPTIDES PANEL VOTES "YES" ON 6 OUT OF 7 PEPTIDES 1. BPC-157 2. KPV 3. TB-500 4. MOTS-C 5. EPITALON 6. SEMAX THE ONE "NO" VOTE: EMIDELTIDE
21
30
9
409
45,451
Emily Passer retweeted
Excited to introduce Lose for Keeps — Noom's new campaign featuring Rebel Wilson, now launched across TV, streaming, social, and digital. Medication can create an opening for change. Habits help make it last. Watch the spots and read more here: lnkd.in/gXe5UwKW
1
1
5
838
Emily Passer retweeted
NOOM LAUNCHES FREE VERSION OF ITS GLP-1 COMPANION - Available at no cost to anyone taking a GLP-1, regardless of provider (e.g., $HIMS and Ro) - Preliminary Noom data show that Noom members had roughly 3x stronger weight maintenance after stopping GLP-1s vs control group
3
4
1
56
8,846
Emily Passer retweeted
Noom CEO @geoffcook is heading to the @ftlive x @endpts US Pharma & Biotech Summit on May 14, speaking on a panel tackling longevity medicine's biggest questions: what's driving innovation, where investment is going, and whether it's reaching the people who need it most. Learn more: bit.ly/42Jw94A #FTPharma
1
1
1
592
Emily Passer retweeted
Honored to be named to @TIME's inaugural TIME100 Companies: Industry Leaders list 🙌 The future of health isn't a drug or an app — it's what happens when lasting behavior change meets cutting-edge clinical care. That's what we're building. bit.ly/420Ed0F
1
3
456
Emily Passer retweeted
Tomorrow, Noom HQ in Princeton hosts our inaugural Noom Talks event, starting with Pulitzer Prize-winning journalist @cduhigg. We're diving into GLP-1s and the powerful window they open for habit formation and lasting change. Stay tuned for the recap. 🎤
2
1
2
510
Emily Passer retweeted
🎉 Exciting news! Our Mindful Art Break feature has been nominated for @TheWebbyAwards in the Apps, Software & Immersive - Health, Wellness & Fitness category - built on the belief that a moment of awe can be a moment of healing. Voting is open now through Thursday, April 16 at 11:59pm PDT - cast your vote here: bit.ly/3NAwHpN
1
1
3
389
Emily Passer retweeted
$HIMS $LLY $NVO 🚨 BREAKING: Noom is acquiring a 503A pharmacy to prepare for the peptide boom We sat down with @GeoffCook (Noom CEO) to discuss why vertical integration is so important, how large the peptide market is going to be, and the evolving dynamics between telehealth platforms and big pharma A great episode with one of the best CEOs in the game - thanks again, Geoff! 00:00 - Why pharma needs DTC platforms 03:03 - Noom's 90% revenue growth 05:01 - Why Noom bought Tailor Made Compounding 07:29 - The case for vertical integration 08:56 - Compounded GLP-1s aren't going anywhere 16:48 - The Hims-Novo deal 19:08 - Noom's pitch to next-gen pharma 24:24 - Peptide market sizing 25:33 - Why GLP-1 users will buy peptides first 27:22 - Ten million potential peptide patients 👀 30:09 - When will legalization happen? 31:09 - Tracking the FDA green list 34:26 - Who wins when peptides go legal? 37:58 - Why Noom won't rush peptide launch 39:33 - Geoff's BPC-157 ski injury recovery 46:42 - Expanding at-home labs past 30 biomarkers 52:47 - Noom IPO coming?! Not financial, legal, or medical advice
9
19
4
225
55,920
Emily Passer retweeted
🚨 Excited to announce that Noom CEO @geoffcook will be returning to the $HIMS House podcast next week
2
3
1
104
8,937
Emily Passer retweeted
💡 11 out of 12 people stop taking GLP-1s within a few years. GLP-1 therapy opens the door to change, but it doesn’t replace the need for sustained behavioral support. That was the message from Noom CEO @geoffcook at the Stanford Consumer Health Summit. Read the full story via @athletechnews 🔗 bit.ly/3PfiRt4
1
2
443
.@noom's CEO @geoffcook on what's next for GLP-1s: "We will see GLP-1s disrupt the supplement industry as they become the entry point for prescription-grade wellness." Good expert roundup on where the category goes from here. 👇
Where does the GLP-1 story go from here? 👀 In a new expert roundup on what's next for GLP-1s, industry leaders weigh in - including Noom CEO @geoffcook, who shares how this drug class may help shape the future of proactive care. Read more: bit.ly/4d1dgAw
1
115
Emily Passer retweeted
We're honored to debut on @Newsweek's Most Trusted Brands 2026 list ✨ The article highlights how Noom continues to evolve - from habit science and GLP-1 support to biomarker testing and ongoing research - all in service of empowering everyone, everywhere to live better, longer every day. Read the article featuring @geoffcook: bit.ly/3M9Wkge
2
1
2
453
New from @noom! Most logged foods by state: How Americans really eat... Quick questions... Missouri? Crab Rangoon? Really? Also, people of Arkansas who inputted just plain black coffee... are you okay? noom.com/blog/nutrition/most…
1
74
Some *personal news* (a 🧵 🪡 )… After more than 3.5 years, I’m moving on from Pagaya, where I was incredibly grateful to have worked with some wicked smart folks, share a powerful growth story and the company's important mission of expanding financial opportunity. 1/4
1
2
164
I’m energized by the opportunity to help shape and share their story at such an important moment in our health culture. You can check out some more here: noom.com/blog/ 4/4 :fin:
2
68